Pfizer on Friday announced that it has plans to launch two or three generic drugs in India by December, reported Indiainfoline. It is an attempt to boost sales and market share in India, said Kewal Handa, managing director, Pfizer India.
Handa also stated that last month, Pfizer has launched telmisartan, an anti-hypertensive drug.
Handa, as quoted to IndiaInfoline: “We wanted to re-look at our portfolio. We wanted to enlarge our portfolio. We are launching this as a part of our increasing product portfolio and market expansion strategy.”
Earlier in May, Pfizer has signed licensing agreements with Aurobindo Pharma and Claris Lifesciences for their off-patent drugs in India. Pfizer also plans to outsource manufacturing for these drugs.